Mankind Pharma Approves Unaudited Standalone and Consolidated Results for Quarter Ended September 30, 2025
Mankind Pharma's board approved unaudited standalone and consolidated financial results for the quarter ended September 30, 2025. Standalone revenue from operations was ₹2,608.78 crore and profit was ₹458.90 crore.
Quarterly results announcements typically have a medium impact as they provide insights into the company's financial performance.
The announcement is a factual disclosure of quarterly results and board meeting outcomes, without explicit positive or negative language.
* Mankind Pharma Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, in a meeting held on November 6, 2025. * The results were reviewed by M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., Joint Statutory Auditors. * The meeting commenced at 03:00 p.m. (IST) and concluded at 04:00 p.m. (IST). * Standalone revenue from operations for the quarter ended September 30, 2025, was ₹2,608.78 crore. * Standalone profit for the period from continuing operations was ₹458.90 crore. * Basic EPS from continuing operations was ₹11.12. * Income tax proceedings uncertainty regarding initiated against the Company by the Income tax Department in an earlier year under Section 132 of Income Tax Act, 1961, appeal against which is currently pending with the appellate tax authorities. * The company completed the transfer of OTC business undertaking as a going concern on a slump sale basis through a Business Transfer Agreement (“BTA”) on September 30, 2024.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.